The Latest Cardiac and Vascular News
IRVINE, Calif.–(BUSINESS WIRE)–TherOx, Inc., a privately held medical device company focused on improving treatment of acute myocardial infarction (AMI), announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its SuperSaturated Oxygen (SSO2) Therapy. SSO2 Therapy provides interventional cardiologists with the first and only FDA-approved treatment beyond percutaneous […]
SUNNYVALE, Calif., April 03, 2019 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq:SILK) (“Silk Road Medical”) today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $20.00 per share. All of the shares of common stock are being offered by Silk […]
CAMPBELL, Calif., April 4, 2019 /PRNewswire/ — Tioga Medical, a newly formed Shifamed portfolio company, announced today the closing of its Series A preferred stock financing, raising a total of $15M. Tioga Medical was founded to provide physicians and patients with an elegant transcatheter valve replacement experience that is procedurally simpler and less invasive […]
SANTA CLARA, Calif., April 03, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, has completed enrollment of its DISRUPT CAD II study, a regulatory-required European post-market registry of coronary IVL. IVL is […]
Orlando, Florida, April 03, 2019 (GLOBE NEWSWIRE) — The Journal of Heart and Lung Transplantation is releasing its themed issue on Mechanical Circulatory Support to coincide with the 39th Annual Meeting of the International Society for Heart and Lung Transplantation being held April 3 – 6 in Orlando, Florida. This special issue highlights […]
Orlando, Florida, April 03, 2019 (GLOBE NEWSWIRE) — A common heart pump has traditionally been seen as only a short-term option for heart-failure patients but new research shows it may provide a similar quality of support as a permanent treatment in patients ineligible for transplantation. The study, part of the […]
SAN FRANCISCO, April 03, 2019 (GLOBE NEWSWIRE) — InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases, today announced the appointment of Daniel G. Welch as executive chairman of the company’s board of directors, effective March 7, 2019. Mr. Welch possesses more than 30 […]
TUCSON, Arizona, April 3, 2019 /PRNewswire/ — SynCardia Systems, LLC, manufacturer of the world’s only clinically-proven and commercially approved total artificial heart, is pleased to announce that Don Webber has been promoted to Chief Executive Officer, and Peter Spadaro has been appointed as the President and Chief Commercial Officer (CCO). Don Webber joined SynCardia in 2018 as […]
GENT, Belgium–(BUSINESS WIRE)–FEops, a leader in personalized predictive planning for structural heart interventions, today announced that FEops HEARTguideTM has received CE mark approval. FEops HEARTguideTM is a one-in-its-kind procedure planning environment for structural heart interventions that provides physicians unique insights to evaluate device sizing and positioning pre-operatively using novel computational modeling and simulation technology. The current release […]
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2018, filed its annual 10-K with the Securities and Exchange Commission, and shared recent business highlights. Recent Business […]
